GlassScriptPhysician profile
David N Oubre
NPI 1104883305
$81,027.32
in general payments reported to CMS, 2019-2025
98 companies · $7,477 in 2025
The $7,477 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $31K · 2021: $4,554 · 2022: $10K · 2023: $7,949 · 2024: $3,207 · 2025: $7,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $7,433 · Travel and Lodging: $693 · Education: $301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,206.93 |
| Consulting Fee | $7,432.50 |
| Travel and Lodging | $692.84 |
| Education | $301.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $17,919.49 | 2019-2025 | |
| Daiichi Sankyo INC. | $12,979.59 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Sobi, INC | $6,917.39 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $5,137.88 | 2019-2025 | Enhertu, Calquence, Imfinzi |
| Rigel Pharmaceuticals, INC. | $4,677.83 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Gilead Sciences, INC. | $4,546.03 | 2019-2025 | Trodelvy |
| Abbvie INC. | $3,304.66 | 2019-2025 | |
| Pfizer INC. | $3,149.48 | 2019-2025 | |
| Glaxosmithkline, LLC. | $2,346.25 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Takeda Pharmaceuticals U.S.A., INC. | $2,052.99 | 2019-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Seagen INC. | $1,806.65 | 2019-2023 | Adcetris, Tukysa |
| Novartis Pharmaceuticals Corporation | $1,570.13 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,110.38 | 2019-2025 | Keytruda, Welireg, Reblozyl |
| Celgene Corporation | $976.30 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| E.R. Squibb & Sons, L.L.C. | $874.05 | 2019-2025 | Opdivo, Opdualag |
Show all 91 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $754.36 | 2019-2025 | Erleada, Tecvayli, Talvey |
| Eisai INC. | $708.46 | 2020-2025 | |
| Incyte Corporation | $608.98 | 2019-2025 | Jakafi, Monjuvi |
| Astellas Pharma US INC | $606.70 | 2019-2025 | Xtandi, Vyloy, Padcev |
| Amgen INC. | $527.32 | 2019-2023 | Lumakras, Kyprolis, Blincyto |
| Genzyme Corporation | $492.50 | 2019-2025 | |
| Asd Specialty Healthcare, LLC | $459.35 | 2022-2025 | |
| Puma Biotechnology, INC. | $429.30 | 2019-2025 | Nerlynx |
| Genentech USA, INC. | $414.58 | 2019-2025 | Polivy, Tecentriq, Venclexta |
| Pharmacyclics LLC, An Abbvie Company | $397.67 | 2019-2023 | Imbruvica |
| Regeneron Healthcare Solutions, INC. | $356.22 | 2019-2025 | Libtayo, Lynozyfic |
| Pharmaessentia USA Corporation | $328.00 | 2022-2025 | Besremi |
| Tesaro, INC. | $273.74 | 2019 | |
| Morphosys, US INC. | $267.84 | 2021-2024 | Monjuvi |
| Emd Serono, INC. | $252.92 | 2019-2025 | Bavencio |
| Aveo Pharmaceuticals, INC. | $242.46 | 2021-2025 | Fotivda |
| Beigene USA, INC. | $235.73 | 2020-2025 | Brukinsa |
| Karyopharm Therapeutics INC. | $230.91 | 2020-2025 | Xpovio |
| Dova Pharmaceuticals | $228.82 | 2019-2021 | |
| Kite Pharma, INC. | $213.47 | 2020-2024 | Yescarta |
| Blueprint Medicines Corporation | $202.17 | 2020-2023 | Ayvakit |
| Intrinsiq Specialty Solutions, INC. | $165.37 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $163.56 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $155.06 | 2021-2025 | Somatuline Depot, Onivyde, Tazverik |
| Servier Pharmaceuticals LLC | $142.35 | 2023-2025 | |
| Tempus Ai, INC | $135.49 | 2024 | |
| Array Biopharma INC | $126.62 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Taiho Oncology, INC. | $122.88 | 2021-2024 | |
| Stemline Therapeutics INC. | $122.30 | 2023-2025 | Orserdu |
| Exelixis INC. | $117.42 | 2020-2025 | Cabometyx |
| Adaptive Biotechnologies Corporation | $106.57 | 2023-2025 | Clonoseq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.61 | 2020-2022 | |
| Tersera Therapeutics LLC | $99.01 | 2025 | Xermelo, Zoladex |
| Kyowa Kirin, INC. | $97.54 | 2019-2022 | |
| Lilly USA, LLC | $96.02 | 2019-2025 | Jaypirca, Verzenio |
| Verastem, INC. | $90.57 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $85.09 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $82.47 | 2020-2022 | |
| Myovant Sciences INC. | $77.65 | 2021-2022 | |
| Foundation Medicine, INC. | $75.16 | 2021-2023 | |
| Jazz Pharmaceuticals INC. | $74.14 | 2020-2025 | |
| Coherus Oncology, INC. | $69.19 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $68.54 | 2019-2022 | |
| Pharmacosmos Therapeutics INC. | $66.70 | 2021-2025 | Monoferric |
| Genmab U.S., INC. | $57.46 | 2024-2025 | Tivdak |
| Geron Corporation | $56.72 | 2025 | Rytelo |
| Epizyme, INC. | $52.10 | 2020-2021 | |
| Cti Biopharma Corp. | $51.83 | 2022-2023 | Vonjo |
| Spectrum Pharmaceuticals INC. | $47.63 | 2023-2024 | Rolvedon |
| Caris Mpi, INC. | $47.18 | 2025 | Mi Cancer Seek |
| Fennec Pharmaceuticals, INC. | $43.51 | 2025 | Fyarro |
| Cumberland Pharmaceuticals, INC. | $41.13 | 2024-2025 | Sancuso |
| Beone Medicines USA, INC. | $40.45 | 2025 | Brukinsa |
| Mirati Therapeutics, INC. | $38.24 | 2023 | Krazati |
| Macrogenics, INC. | $36.65 | 2021 | |
| Adc Therapeutics America, INC. | $35.19 | 2023 | |
| Springworks Therapeutics, INC. | $34.20 | 2025 | Ogsiveo |
| Veracyte, INC. | $32.82 | 2023-2024 | |
| Agios Pharmaceuticals, INC. | $32.53 | 2022-2024 | |
| Syndax Pharmaceuticals, INC. | $31.79 | 2025 | |
| Clovis Oncology, INC. | $31.76 | 2019-2020 | |
| Organon LLC | $26.64 | 2023-2024 | Ontruzant |
| Secura Bio, INC. | $26.32 | 2020 | |
| Amag Pharmaceuticals, INC. | $24.30 | 2019-2022 | |
| Deciphera Pharmaceuticals INC. | $19.59 | 2022 | |
| Dendreon Pharmaceuticals LLC | $18.92 | 2025 | Provenge |
| Recordati_rare_diseases_inc. | $17.64 | 2025 | Sylvant |
| Lexicon Pharmaceuticals, INC. | $17.60 | 2020 | |
| Medtronic USA, INC. | $17.54 | 2019 | |
| Myriad Genetic Laboratories, INC. | $16.45 | 2022 | |
| Tg Therapeutics, INC. | $16.36 | 2021 | |
| Heron Therapeutics, INC. | $15.56 | 2019 | |
| Clinigen, INC. | $15.14 | 2020 | |
| G1 Therapeutics, INC. | $15.01 | 2022 | |
| Mylan Institutional INC. | $14.75 | 2019 | |
| Sumitomo Pharma America, INC. | $14.40 | 2023 | Orgovyx |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$85,509.38 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Oubre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.